The "INTELLIH" (brand name of the mobile health application) Diabetes Study is to understand the usage of a mobile health application, IntelliH, and connected wireless devices such as glucometer by the diabetic patients and ascertain if there are any improvements in short-term health outcomes.

The proposed pilot program is the first of its kind in the nation to use a product, "IntelliH" - Intelligent Health for All, that combines four key technologies in one platform: 1) Mobile health application (mHealth) App and web portal, 2) wireless sensors and wearable devices, 3) Secure text messaging when both sender and receiver are logged in to the system and video-based patient interaction, and 4) remote health monitoring. The purpose of this pilot program is to understand a) usage and adoption of these technologies by providers and patients, and b) document the short-term improvements in health outcomes in a diabetic population. This pilot study will follow 20 diabetic patients (Type 1 or Type 2) as they beta-test this system, and will acquire data on consented subjects over a period of six months.

Inclusion Criteria:

• A1c greater than or equal to 6.5%.
• Age greater than or equal to 18 years.
• Ability to comply with study protocol.
• Available and usable internet facilities at home.
• Availability and usable smart phone.

Exclusion Criteria:

-Inability to comply with instructions and directions.

Study participants will be recruited from the list of diabetes patients coming to Cedars-Sinai Medical Center for their regular treatment. Several physicians will be involved in making this program available to their patients. Eligible and consenting patients will be recruited.